We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: UK stocks retreat from 14-year high, BoE in focus

Wed, 14th May 2014 08:43

- FTSE 100 pulls back after nearing record- BoE in focus ahead of inflation report- UK employment data due out- Compass unveils 1bn-pound cash returntechMARK 2,798.34 -0.21%FTSE 100 6,857.97 -0.22%FTSE 250 16,046.94 +0.05%UK stocks declined on Wednesday morning as investors took profits after markets closed at a 14-year high the previous session.The FTSE 100 was down 0.2% at 6,858 in early trading after hitting 6,873.08 on Tuesday, its best finish since reaching a record closing high of 6,930 at the end of December 1999."Whilst the markets have demonstrated a remarkable ability to shrug off the crisis in the Ukraine and interpret weak China data as a positive, there is a sense of foreboding about this upward move," said Jonathan Sudaria, a dealer at Capital Spreads.The Bank of England (BoE) is due to release new inflation and growth forecasts later today as the central bank comes under pressure to raise interest rates amid soaring house prices. The BoE has vowed to keep interest rates at a record low of 0.5% for an extended period but fears of a housing bubble have raised questions on whether the bank will move sooner to lift rates.Ahead of the interest rate report at 10:30, data is expected to show the unemployment rate fell again to 6.8% in the three months to March from 6.9% in the preceding three months. Employers during the period are projected to have added 248,000 new jobs, compared to 239,000 the previous quarter. Compass jumps after special dividendCatering giant Compass rose strongly this morning as the company hiked its interim dividend after a solid first half and unveiled a £1bn capital return to investors. "Strong cash generation has underpinned our investment in the business and our commitment to reward shareholders," said Chief Executive Richard Cousins.Paper and packaging group Mondi was also higher after delivering a 13% increase in underlying operating profits in the first quarter despite a "mixed" trading environment and flat sales volumes.Mining stocks were trading slightly lower this morning as sentiment in the industry was dampened by the news that over 200 people have been killed after an electrical fault at a mine triggered an explosion in western Turkey. Randgold Resources was a notable faller this morning.UK car insurer Admiral declined after reporting a 7% drop in first-quarter revenue as premiums continued to fall.Television network ITV underwhelmed with in-line ad revenues in the first quarter. However, the second quarter looks to beat expectations thanks to a spike in World Cup-related ads. Healthcare services provider UDG Healthcare impressed as it raised its full-year profit guidance, helped by a decent first half and the recent acquisition of the KnowledgePoint360 business.A number of heavyweight stocks were trading lower this morning after going ex-dividend, including Aberdeen Asset Management, Sage, GlaxoSmithKline, Shell, Glencore Xstrata, Kingfisher and J Sainsbury.FTSE 100 - RisersCompass Group (CPG) 1,029.00p +4.95%Mondi (MNDI) 1,054.00p +2.23%Aggreko (AGK) 1,710.00p +1.73%Petrofac Ltd. (PFC) 1,235.00p +1.48%RSA Insurance Group (RSA) 486.60p +0.72%easyJet (EZJ) 1,670.00p +0.72%Experian (EXPN) 1,072.00p +0.66%United Utilities Group (UU.) 840.00p +0.66%Babcock International Group (BAB) 1,248.00p +0.65%Vodafone Group (VOD) 221.25p +0.64%FTSE 100 - FallersITV (ITV) 181.90p -4.76%Sainsbury (J) (SBRY) 325.80p -3.89%Glencore Xstrata (GLEN) 324.20p -1.95%Randgold Resources Ltd. (RRS) 4,508.00p -1.81%Aberdeen Asset Management (ADN) 428.00p -1.72%Kingfisher (KGF) 410.90p -1.58%GlaxoSmithKline (GSK) 1,617.00p -1.22%Royal Dutch Shell 'B' (RDSB) 2,556.50p -1.16%Admiral Group (ADM) 1,433.00p -1.04%Royal Dutch Shell 'A' (RDSA) 2,346.50p -0.99%FTSE 250 - Risers3i Group (III) 393.60p +4.04%Partnership Assurance Group (PA.) 128.00p +3.06%Wood Group (John) (WG.) 792.50p +2.99%Galliford Try (GFRD) 1,215.00p +2.71%Booker Group (BOK) 154.10p +2.46%UDG Healthcare Public Limited Company (UDG) 368.00p +2.22%Senior (SNR) 293.70p +1.98%JD Sports Fashion (JD.) 1,735.00p +1.88%Euromoney Institutional Investor (ERM) 1,143.00p +1.60%Kentz Corporation Ltd. (KENZ) 720.50p +1.55%FTSE 250 - FallersRenishaw (RSW) 1,760.00p -4.30%Carillion (CLLN) 355.00p -3.32%Barr (A.G.) (BAG) 603.50p -2.35%Fidessa Group (FDSA) 2,294.00p -2.17%Perform Group (PER) 260.00p -1.89%Supergroup (SGP) 1,089.00p -1.89%PayPoint (PAY) 1,130.00p -1.74%Pace (PIC) 378.90p -1.71%Rank Group (RNK) 161.80p -1.64%Inmarsat (ISAT) 719.00p -1.64%BC
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.